Millet seed supplement shows promise for hair loss in women
NCT ID NCT07348120
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether millet seed extract capsules can reduce hair shedding in women with telogen effluvium, a common temporary hair loss condition. Sixty women took either the millet seed supplement or biotin alone for 12 weeks. Researchers measured changes in hair density using a special scalp camera and asked about satisfaction.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- millet seed extract with biotin, L-cystine, and vitamin B5
- What this could lead to
- If it works, this could point toward a natural supplement option for managing temporary hair loss in women.
- What could go wrong
- This is a small, completed trial with only 60 participants, so results may not apply to everyone. The supplement is compared to biotin alone, and the effect may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Hair shedding degree of 4 or higher according to the Hair Shedding Visual Scale (Sinclair scale). * Diagnosis of telogen effluvium confirmed by a dermatologist after ruling out other causes of non-scarring alopecia (e.g., alopecia areata, androgenetic alopecia). * No use of topical or systemic hair loss treatments or oral hair growth supplements for at least 1 month prior to the study. Exclusion Criteria: * Pregnancy or breastfeeding. * History of scalp diseases or conditions affecting hair growth like androgenic alopecia and alopecia areata. * Use of medications known to cause hair loss. * Any underlying medical condition that could interfere with the study. * Use of topical treatment in the last 3 month. * Use of systemic treatment in the last 3 month such as iron, biotin or any hair growth supplements. * Annemia or low serum level of ferritin.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Telogen effluvium are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kasr El Aini Hospital
Cairo, Cairo Governorate, 11555, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.